Yuki Noguchi
Chugai Pharma (United States)(US)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, Immunotherapy and Immune Responses, Cell Adhesion Molecules Research, Monoclonal and Polyclonal Antibodies Research, Mast cells and histamine
Most-Cited Works
- → Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation(2020)97 cited
- → GATA2 is critical for the maintenance of cellular identity in differentiated mast cells derived from mouse bone marrow(2015)53 cited
- → Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia(2018)28 cited
- → Phospholipid scrambling induced by an ion channel/metabolite transporter complex(2024)9 cited
- → Chlorambucil-conjugated PI-polyamides (Chb-M’), a transcription inhibitor of RUNX family, has an anti-tumor activity against SHH-type medulloblastoma with p53 mutation(2022)7 cited
- → In vivo CRISPR screening directly targeting testicular cells(2024)6 cited
- → Suppression of malignant rhabdoid tumors through Chb‐M′‐mediated RUNX1 inhibition(2020)6 cited
- → Pharmacokinetic prediction of an antibody in mice based on an in vitro cell-based approach using target receptor-expressing cells(2020)5 cited
- → Genome-Wide Screening Approaches for Biochemical Reactions Independent of Cell Growth(2024)2 cited
- → Protocol for in vivo CRISPR screening targeting murine testicular cells(2024)1 cited